First Wave BioPharma

AzurRx BioPharma, headquartered in New York with a research facility in Longrades, France, is a biopharmaceutical company in the development stage. It went public through an IPO in 2016 at an issue price of $5.5. The company focuses on recombinant enzymes for treating gastrointestinal diseases and microbiota-related conditions, with two main products: MS1819, a recombinant lipase for treating exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and AZX1101, a recombinant enzyme for preventing hospital-acquired Clostridium difficile infection (CDI).On September 13, 2021, AzurRx BioPharma, Inc. completed the acquisition of First Wave BioPharma, Inc., a clinical-stage biotechnology company.On September 21, 2021, AzurRx BioPharma, Inc. officially announced its name change to First Wave BioPharma, Inc. Starting from September 22, its stock trading symbol on NASDAQ changed from AZRX to FWBI.